Bank Julius Baer & Co. Ltd Zurich acquired a new position in Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 2,040 shares of the medical research company’s stock, valued at approximately $203,000.
Several other hedge funds have also made changes to their positions in NTRA. Capstone Triton Financial Group LLC bought a new stake in shares of Natera in the fourth quarter worth $37,000. Harvest Fund Management Co. Ltd acquired a new position in Natera during the fourth quarter worth $39,000. James Investment Research Inc. acquired a new position in Natera during the fourth quarter worth $50,000. Heritage Wealth Advisors increased its holdings in Natera by 18.8% during the fourth quarter. Heritage Wealth Advisors now owns 855 shares of the medical research company’s stock worth $85,000 after buying an additional 135 shares during the last quarter. Finally, Sittner & Nelson LLC acquired a new position in Natera during the fourth quarter worth $100,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.
In related news, COO Robert Alan Schueren sold 2,066 shares of the company’s stock in a transaction dated Friday, January 8th. The shares were sold at an average price of $109.32, for a total transaction of $225,855.12. Following the completion of the sale, the chief operating officer now owns 53,340 shares of the company’s stock, valued at $5,831,128.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Todd C. Cozzens sold 29,475 shares of the company’s stock in a transaction dated Tuesday, March 9th. The stock was sold at an average price of $100.35, for a total transaction of $2,957,816.25. Following the sale, the director now directly owns 36,753 shares of the company’s stock, valued at approximately $3,688,163.55. The disclosure for this sale can be found here. In the last three months, insiders sold 151,164 shares of company stock valued at $15,039,386. 9.29% of the stock is currently owned by company insiders.
Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 25th. The medical research company reported ($0.89) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.28). Natera had a negative net margin of 52.11% and a negative return on equity of 53.39%. Equities research analysts predict that Natera, Inc. will post -2.48 earnings per share for the current fiscal year.
A number of equities analysts recently weighed in on NTRA shares. Craig Hallum boosted their target price on shares of Natera from $92.00 to $118.00 and gave the stock a “buy” rating in a report on Monday, January 4th. Canaccord Genuity boosted their target price on shares of Natera from $112.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, January 14th. BTIG Research upped their price objective on shares of Natera from $112.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, January 19th. Truist started coverage on shares of Natera in a report on Wednesday, January 27th. They issued a “buy” rating and a $143.00 price objective on the stock. Finally, Piper Sandler upped their price objective on shares of Natera from $127.00 to $150.00 and gave the company an “overweight” rating in a report on Thursday, March 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $102.33.
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Marijuana Stocks
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.